Introduction
Background
Ulcerative colitis (UC) is an idiopathic chronic inflammatory disorder limited to the colon (see the image below). Ulcerative colitis is a lifelong illness that has a profound emotional and social impact on patients who are affected.
Pathophysiology
The rectum is involved in more than 95% of cases, although some authorities believe that the rectum is always involved in untreated patients. Ulcerative colitis extends proximally from the anal verge in an uninterrupted pattern to involve part or all of the colon.
Frequency
United States
The annual incidence of ulcerative colitis is 10.4-12 cases per 100,000 people. The prevalence rate is 35-100 cases per 100,000 people.
International
Prevalence rates may be lower in South America, Asia, and Africa.
Race
- Ulcerative colitis occurs more frequently in white people.
- The incidence of ulcerative colitis is reported to be 2-4 times higher in Jewish people. However, population studies in North America do not completely support this assertion.
Sex
Ulcerative colitis seems to have a female preponderance. Ulcerative colitis affects 30% more females than males.
Age
The incidence of ulcerative colitis peaks in people aged 15-25 years and in people aged 55-65 years, although it can occur in people of any age.1
Clinical
History
- Frequent episodes of rectal bleeding occur, with or without mucus. The characteristic feature is blood in each bowel movement.
- Urgency and tenesmus
- Abdominal cramps
- Weight loss in severe cases
- Extracolonic manifestations
- Synovitis
- Ankylosing spondylitis (HLA-B27)
- Sacroiliitis
- Erythema nodosum
- Pyoderma gangrenosum
- Aphthous stomatitis
- Episcleritis
- Iritis
- Primary sclerosing cholangitis (PSC)
- Uric acid renal stones
- Rarely, thromboembolic events or syndromes (CNS venous thrombosis)
Physical
Physical findings are typically normal in patients with mild disease, except for mild tenderness in the lower left quadrant.
Patients with severe disease can have signs of volume depletion and toxicity, including the following:
- Fever
- Tachycardia
- Significant abdominal tenderness
- Weight loss
Causes
- Autoimmune phenomena: Serum and mucosal autoantibodies against intestinal epithelial cells may be involved. Persons with ulcerative colitis are often found to have p-antineutrophil cytoplasmic antibodies.
- Immune-mediated phenomena: Abnormalities of humoral and cell-mediated immunity and/or generalized enhanced reactivity against intestinal bacterial antigens may be causes. A loss of tolerance against indigenous enteric flora is believed to be the central event in the pathogenesis of inflammatory bowel disease (IBD).
- Genetic susceptibility (chromosomes 12 and 16) is a factor associated with ulcerative colitis. A positive family history (observed in 1 in 6 relatives) is associated with a higher risk for developing the disease.
- Smoking is negatively associated with ulcerative colitis. This relationship is reversed in Crohn disease.
- Environmental factors may be involved.
- Dietary factors: Milk consumption may exacerbate the disease.
- Appendectomies have a negative association with ulcerative colitis.
More on Ulcerative Colitis |
Overview: Ulcerative Colitis |
| Differential Diagnoses & Workup: Ulcerative Colitis |
| Treatment & Medication: Ulcerative Colitis |
| Follow-up: Ulcerative Colitis |
| Multimedia: Ulcerative Colitis |
| References |
| Further Reading |
| Next Page » |
References
Jang ES, Lee DH, Kim J, et al. Age as a clinical predictor of relapse after induction therapy in ulcerative colitis. Hepatogastroenterology. Sep-Oct 2009;56(94-95):1304-9. [Medline].
Andersson T, Lunde OC, Johnson E, et al. Long-term functional outcome and quality of life after restorative proctocolectomy with ileo-anal anastomosis for colitis. Colorectal Dis. Dec 14 2009;[Medline].
da Luz Moreira A, Kiran RP, Lavery I. Clinical outcomes of ileorectal anastomosis for ulcerative colitis. Br J Surg. Jan 2010;97(1):65-9. [Medline].
[Best Evidence] Sandborn WJ, Rutgeerts P, Feagan BG, et al. Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab. Gastroenterology. Oct 2009;137(4):1250-60; quiz 1520. [Medline].
Parente F, Molteni M, Marino B, et al. Are colonoscopy and bowel ultrasound useful for assessing response to short-term therapy and predicting disease outcome of moderate-to-severe forms of ulcerative colitis?: a prospective study. Am J Gastroenterol. Dec 8 2009;[Medline].
Pekow JR, Hetzel JT, Rothe JA, et al. Outcome after surveillance of low-grade and indefinite dysplasia in patients with ulcerative colitis. Inflamm Bowel Dis. Dec 21 2009;[Medline].
Alcalde Encinas MM, Perez-Gracia A, Hallal H, et al. [Cerebral venous sinus thrombosis and ulcerative colitis]. Rev Esp Enferm Dig. Feb 2000;92(2):105-8. [Medline].
Brown MO. Inflammatory bowel disease. Prim Care. Mar 1999;26(1):141-70. [Medline].
Fichera A, Michelassi F. Indication for surgery: a surgeon's opinion. In: Sartor RB, Sandborn WJ. Kirsner's Inflammatory Bowel Diseases. 6th ed. New York: Saunders; 2004:596-601/39.
Froehlich F, Larequi-Lauber T, Gonvers JJ, et al. 11. Appropriateness of colonoscopy: inflammatory bowel disease. Endoscopy. Oct 1999;31(8):647-53. [Medline].
Hanauer SB. Inflammatory bowel disease. N Engl J Med. Mar 28 1996;334(13):841-8. [Medline].
Itzkowitz SH, Present DH. Consensus conference: Colorectal cancer screening and surveillance in inflammatory bowel disease. Inflamm Bowel Dis. Mar 2005;11(3):314-21. [Medline].
Jayanthi V, Probert CS, Mayberry JF. Epidemiology of inflammatory bowel disease. Q J Med. Jan 1991;78(285):5-12. [Medline].
Kamm MA, Sandborn WJ, Gassull M, et al. Once-daily, high-concentration MMX mesalamine in active ulcerative colitis. Gastroenterology. Jan 2007;132(1):66-75; quiz 432-3. [Medline].
Kornbluth A, Sachar DB. Ulcerative colitis practice guidelines in adults (update): American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol. Jul 2004;99(7):1371-85. [Medline].
Lichtenstein GR, Abreu MT, Cohen R, et al. American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology. Mar 2006;130(3):940-87. [Medline].
Rioux JD, Silverberg MS, Daly MJ, et al. Genomewide search in Canadian families with inflammatory bowel disease reveals two novel susceptibility loci. Am J Hum Genet. Jun 2000;66(6):1863-70. [Medline].
Stenson WF, Korzenik J. Inflammatory bowel disease. In: Yamada T, ed. Textbook Of Gastroenterology. Vol 2. 4th ed. Philadephia: Lippincott Williams & Wilkins; 2003:1699-1759.
Thomas GA, Rhodes J, Green JT. Role of smoking in inflammatory bowel disease: implications for therapy. Postgrad Med J. May 2000;76(895):273-9. [Medline].
Tremaine WJ. Collagenous colitis and lymphocytic colitis. J Clin Gastroenterol. Apr 2000;30(3):245-9. [Medline].
Further Reading
Related eMedicine Topics
- Crohn Disease [in the Gastroenterology section]
- Crohn Disease [in the Radiology section]
- Inflammatory Bowel Disease [in the Gastroenterology section]
- Inflammatory Bowel Disease [in the Emergency Medicine section]
- Ulcerative Colitis [in the Pediatrics: General Medicine section]
- Ulcerative Colitis [in the Pediatrics: Surgery section]
- Ulcerative Colitis [in the Radiology section]
Clinical Trials
- (CB-01-02/01) Randomized Placebo Controlled Trial of Budesonide-MMX™ (CB-01-02) 6 mg and 9 mg in Patients With Ulcerative Colitis
- Colon Capsule Endoscopy Versus Standard Colonoscopy in Ulcerative Colitis
- Efficacy and Safety of Asacol™ 4.8 g/Day (800 mg Tablets) for the Treatment of Active Ulcerative Colitis
- Immune Regulation in Ulcerative Colitis or Crohn's Disease
- Melatonin & Ulcerative Colitis
- Safety and Activity of ORE1001 in Subjects With Ulcerative Colitis
- Study Comparing Cyclosporine With Infliximab in Steroid-refractory Severe Attacks of Ulcerative Colitis
Clinical Guidelines
- American Gastroenterological Association Institute medical position statement on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. American Gastroenterological Association Institute - Medical Specialty Society. 2006 Mar. 5 pages. NGC:004873
- ASGE guideline: endoscopy in the diagnosis and treatment of inflammatory bowel disease. American Society for Gastrointestinal Endoscopy - Medical Specialty Society. 2006 Apr. 8 pages. NGC:004977
- Evidence-based care guideline for management of pediatric moderate/severe inflammatory bowel disease (IBD). Cincinnati Children's Hospital Medical Center - Hospital/Medical Center. 2007 Apr 5. 29 pages. NGC:005604
- Guidelines for osteoporosis in inflammatory bowel disease and coeliac disease. British Society of Gastroenterology - Medical Specialty Society. 2007 Jun. 18 pages. NGC:007149
- Infliximab for acute exacerbations of ulcerative colitis. National Institute for Health and Clinical Excellence (NICE) - National Government Agency [Non-U.S.]. 2008 Dec. 25 pages. NGC:007075
- Infliximab for subacute manifestations of ulcerative colitis. National Institute for Health and Clinical Excellence (NICE) - National Government Agency [Non-U.S.]. 2008 Apr. 21 pages. NGC:006482
- Practice parameters for the surgical treatment of ulcerative colitis. American Society of Colon and Rectal Surgeons - Medical Specialty Society. 1997 (revised 2005 Nov). 13 pages. NGC:005612
Keywords
ulcerative colitis, IBS, colitis, Crohn’s disease, Crohn disease, irritable bowel syndrome, IBD, inflammatory bowel disease, ulcerative colitis treatment, ulcerative colitis symptoms, colonic inflammation, rectal inflammation, toxic megacolon, ileus, diverticulitis, primary sclerosing cholangitis, rectal bleeding, bloody bowel movements


Overview: Ulcerative Colitis